Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Cancer|August 9, 2018
Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK ExpressionHarald Hessel, Manuela Poignée-Heger, Sabine Lohmann, et al.
Nucleic Acid Therapeutics|November 8, 2025
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ ConsortiumJoanna Grudzinska-Goebel, Manuela Braun, Lin-Zhi Chen, et al.
Mabs|June 22, 2026
Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variantsTatjana Sela, Tamara Wirth, Annika Sommer, et al.
Methods (San Diego, Calif.)|July 17, 2012
Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assaysSabine Lohmann, Andrea Herold, Tobias Bergauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2015
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer PatientsFabian Birzele, Edgar Voss, Adam Nopora, et al.
Nucleic Acid Therapeutics|September 30, 2022
Assessment of the Immunogenicity Potential for Oligonucleotide-Based DrugsScott P Henry, Cecilia Arfvidsson, Josh Arrington, et al.
Nucleic Acids Research|October 30, 2025
Improved targeted delivery of antisense oligonucleotide with an antibody maskHung-En Hsia, Chiara Zanini, Claire Simonneau, et al.
Bioconjugate Chemistry|November 2, 2023
Diligent Design Enables Antibody-ASO Conjugates with Optimal Pharmacokinetic PropertiesTatjana Sela, Mads Mansø, Michel Siegel, et al.
Blood|March 26, 2013
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patientsAnnika Dufour, Giuseppe Palermo, Evelyn Zellmeier, et al.
Nucleic Acids Research|September 29, 2025
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendationsJesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, et al.
Pageof 1